Main Story
-
Platinum Industries Announces Entry into Life Sciences; Collaborates with Dr. Abhigyan Upadhyay to Lead the New Enterprise, Rivadu Lifesciences Pvt. Ltd.
Strengthens leadership to build a research-driven and globally scalable model in high-value life sciences segments Mumbai, Maharashtra, India Platinum Industries Ltd. [NSE: PLATIND; BSE: 544134], an innovation-driven specialty chemicals company announced its strategic entry into the life sciences sector, marking a significant step in its next phase of growth. As part of this expansion, the…
Automobile
Tech
Entertainment
-
Youth-Centric Debut Film 'Jeena Dil Se' Opens Strong with Rs 1.06 Crore on Day 1
Mumbai, Maharashtra, India The youthful entertaining drama Jeena Dil Se released today has emerged as one of the most surprising openings among small-budget debutant-driven films. Presented by ADR Media Production, the film opened to an impressive Rs 1.06 crore on Day 1 at the box office, a number that has taken everyone by surprise. A strong…
Health
-
Platinum Industries Announces Entry into Life Sciences; Collaborates with Dr. Abhigyan Upadhyay to Lead the New Enterprise, Rivadu Lifesciences Pvt. Ltd.
Strengthens leadership to build a research-driven and globally scalable model in high-value life sciences segments Mumbai, Maharashtra, India Platinum Industries Ltd. [NSE: PLATIND; BSE: 544134], an innovation-driven specialty chemicals company announced its strategic entry into the life sciences sector, marking a significant step in its next phase of growth. As part of this expansion, the…
-
Akums Reports Q4 FY26 and Full Year FY26 Results with Healthy Top Line and Strong EBITDA Growth; Board Recommends Dividend
New Delhi, Delhi, India Akums Drugs & Pharmaceuticals Ltd., India’s largest Contract Development and Manufacturing Organisation (CDMO), announced its financial results for the fourth quarter and the full year ended March 31, 2026. The company delivered a steady performance during Q4 FY26, with healthy revenue growth and improved operating profitability driven by its core domestic…
-
Johnson & Johnson’s Phase 3 prostate cancer study shows ERLEADA® (apalutamide) before and after surgery significantly reduces risk of metastasis or death, versus hormone therapy alone, potentially shifting a decades-long treatment paradigm
Compared with patients receiving hormone therapy alone, patients were nine times more likely to have little to no cancer remaining in the prostate after surgery, with a 20 percent reduction in the risk of developing metastasis or death1 Data selected to open the plenary presentation at ASCO 2026 and published in The New England Journal…
-
Revolution Medicines Announces ASCO Plenary Presentation Highlighting Unprecedented Results from Pivotal Phase 3 RASolute 302 Clinical Trial of Daraxonrasib in Previously Treated Metastatic Pancreatic Cancer
REDWOOD CITY, Calif., May 31, 2026 (GLOBE NEWSWIRE) — Revolution Medicines, Inc. (Nasdaq: RVMD), a late-stage clinical oncology company developing targeted therapies for patients with RAS-addicted cancers, today announced detailed results from the global, randomized Phase 3 RASolute 302 clinical trial evaluating daraxonrasib, an oral RAS(ON) multi-selective inhibitor, in patients with previously treated metastatic pancreatic…
-
World MS Day: National Policy Dialogue Adopts Landmark 10-Point Declaration Calling for Stronger Recognition of Invisible Disabilities in India
~Stakeholders urge reforms across disability certification, healthcare access, insurance, workplace inclusion and national health systems to improve outcomes for people living with Multiple Sclerosis and other invisible neurological conditions~ NEW DELHI, May 30, 2026 /PRNewswire/ — In a significant step towards strengthening disability-inclusive healthcare and social protection in India, Members of Parliament, policymakers, neurologists, disability…
-
Niche Group Advances India's Vision Across Organic Farming and Cancer Treatment
At the same time, he revealed that Niche Agriculture and Pharmaceuticals Limited (NAPL) is working on affordable medicines for diseases such as cancer, epilepsy, and Alzheimer’s. Hundreds of PhD scholars were also interviewed and selected for opportunities during the event. Nestled amidst the beauty of nature, the auditorium of CSKHPKV transformed into far more than…
About the Author
We increase the awareness of millions of users through our news networks. We are one of the most trusted news networks in the world.
